Literature DB >> 2291725

Splenomegaly--an insensitive sign of portal hypertension.

P R Gibson1, R N Gibson, M R Ditchfield, J D Donlan.   

Abstract

The prevalence of splenomegaly associated with portal hypertension was examined in a consecutive population of 111 patients who had portal hypertension diagnosed using specific endoscopic, sonographic, and Doppler signs. Splenic size was measured objectively via its cranio-caudal length on coronal section using ultrasound and by clinical examination. Sonographically, 52% of patients had a definitely large spleen and 35% a spleen less than one standard deviation from the normal mean, while a further 13% had equivocal splenomegaly. Only 52% of patients had splenomegaly on clinical assessment. Splenomegaly was less common in patients with alcoholic (41% definite, 15% equivocal) than in those with non-alcoholic liver disease (66% definite, 17% equivocal, p = 0.02) and splenic length was significantly smaller in alcoholic patients (12.7 +/- 0.5 cm) compared to patients with either non-alcoholic liver disease (15.0 +/- 0.6 cm, p = 0.003) or portal hypertension due to vascular occlusive diseases (16.5 +/- 2.0 cm, p = 0.006). Splenomegaly, whether assessed sonographically or clinically, is an insensitive sign of portal hypertension and its absence cannot be used as a negative predictor of the presence of portal hypertension in patients with chronic liver disease.

Entities:  

Mesh:

Year:  1990        PMID: 2291725     DOI: 10.1111/j.1445-5994.1990.tb00421.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  8 in total

1.  Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis.

Authors:  Theresa Bucsics; Katharina Lampichler; Constantin Vierziger; Maria Schoder; Florian Wolf; David Bauer; Benedikt Simbrunner; Lukas Hartl; Mathias Jachs; Bernhard Scheiner; Michael Trauner; Thomas Gruenberger; Franz Karnel; Mattias Mandorfer; Thomas Reiberger
Journal:  Dig Dis Sci       Date:  2022-03-17       Impact factor: 3.199

2.  Subtotal splenectomy for splenomegaly in cirrhotic patients.

Authors:  Haibo Chu; Xiaofang Liu; Jianhua Zhao; Yongbo Xu; Lei Wang; Tao Wang; Wenjun Guo; Shengming Zhang; Xiaoji Zhu
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

3.  Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension.

Authors:  Jayant A Talwalkar; Meng Yin; Sudhakar Venkatesh; Phillip J Rossman; Roger C Grimm; Armando Manduca; Anthony Romano; Patrick S Kamath; Richard L Ehman
Journal:  AJR Am J Roentgenol       Date:  2009-07       Impact factor: 3.959

Review 4.  Management of thrombocytopenia in advanced liver disease.

Authors:  V G R Gangireddy; P C Kanneganti; S Sridhar; S Talla; T Coleman
Journal:  Can J Gastroenterol Hepatol       Date:  2014-09-15

5.  Non-invasive assessment of portal hypertension by multi-parametric magnetic resonance imaging of the spleen: A proof of concept study.

Authors:  Christina Levick; Jane Phillips-Hughes; Jane Collier; Rajarshi Banerjee; Jeremy F Cobbold; Lai Mun Wang; Stefan K Piechnik; Matthew D Robson; Stefan Neubauer; Eleanor Barnes; Michael Pavlides
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

6.  Man with tarry stools.

Authors:  Hung-Bin Tsai; Chia-Hao Hsu; Chien-Lun Chen; Po-Han Chu; Chen Wei Huang; Nin-Chieh Hsu
Journal:  J Am Coll Emerg Physicians Open       Date:  2021-12-24

7.  Gamna-Gandy bodies of the spleen detected with susceptibility weighted imaging: maybe a new potential non-invasive marker of esophageal varices.

Authors:  Jiuquan Zhang; Ran Tao; Zhonglan You; Yongming Dai; Yi Fan; Jinguo Cui; Qing Mao; Jian Wang
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

8.  Spleen stiffness correlates with the presence of ascites but not esophageal varices in chronic hepatitis C patients.

Authors:  Kazuyo Mori; Hirotaka Arai; Takehiko Abe; Hisashi Takayama; Mitsuo Toyoda; Takashi Ueno; Ken Sato
Journal:  Biomed Res Int       Date:  2013-08-01       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.